CNMD CONMED Corp
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 816956 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY-64.5%
TTM EPS YoY-64.5%
Revenue 3-yr CAGR9.6%
Net income 3-yr CAGR—
Margins
Gross margin54.6%
Operating margin7.5%
Net margin3.4%
FCF margin11.0%
EBITDA margin8.7%
Returns
ROE4.7%
ROA2.0%
ROIC (approx.)3.7%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets55.6%
Debt / equity0.81x
Current ratio2.14x
Interest coverage3.30x
Cash quality & payout
Operating cash flow / net income3.63x
Accruals ratio-5.3%
Payout ratio52.6%
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.37B | $1.31B |
| Cost of revenue | $624.25M | $573.98M |
| Gross profit | $750.48M | $733.03M |
| R&D expense | $55.88M | $54.43M |
| SG&A expense | $591.97M | $478.28M |
| Operating income | $102.62M | $200.33M |
| Interest expense | $31.09M | $37.30M |
| Pretax income | $71.12M | $163.03M |
| Income tax | $24.06M | $30.61M |
| Net income | $47.05M | $132.42M |
| EBITDA | $119.77M | $216.93M |
| EPS (basic) | 1.52 | 4.29 |
| EPS (diluted) | 1.51 | 4.25 |
| Dividends declared per share | 0.60 | 0.80 |
| Weighted avg. shares (diluted) | 31.15M | 31.15M |
| Balance sheet | ||
| Cash & equivalents | $40.82M | $24.46M |
| Receivables | $247.83M | $237.73M |
| Inventory | $355.54M | $346.72M |
| Current assets | $672.86M | $640.01M |
| PP&E, net | $113.33M | $115.79M |
| Goodwill | $807.01M | $805.36M |
| Intangibles | $582.05M | $617.66M |
| Total assets | $2.33B | $2.31B |
| Current liabilities | $315.04M | $278.13M |
| Short-term debt | $712,000 | $715,000 |
| Long-term debt | $834.23M | $905.07M |
| Total debt | $834.94M | $905.78M |
| Total liabilities | $1.29B | $1.34B |
| Shareholders' equity | $1.03B | $962.68M |
| Net debt | $794.12M | $881.32M |
| Cash flow statement | ||
| Operating cash flow | $170.69M | $166.97M |
| Capital expenditure | $19.81M | $13.08M |
| Free cash flow | $150.88M | $153.88M |
| Investing cash flow | -$20.96M | -$13.08M |
| Financing cash flow | -$135.82M | -$151.00M |
| Depreciation & amortization | $17.14M | $16.61M |
| Stock-based compensation | $28.32M | $25.56M |
| Dividends paid | $24.75M | $24.65M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.